RAPHAS
Korea - SeoulBiotechnology
Focus: RAPHAS is a Korea-based biotechnology company specializing in biodegradable microneedle drug delivery patches, currently generating revenue exclusively from XERAVA (eravacycline) for infectious diseases. The company operates as a focused biotech player with a single marketed asset and early-stage pipeline expansion.
Profile data last refreshed 6h ago · AI intelligence enriched 1w ago
Open Jobs
5
Should You Work at RAPHAS?
AI assessmentRAPHAS is a niche biotech with innovative technology but carries significant execution risk due to single-product revenue model and sparse pipeline—best suited for early-career scientists seeking deep technical ownership in emerging delivery platforms.
Why Work Here
- Opportunity to work on innovative microneedle delivery technology platform with differentiated IP in an underexploited modality.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$788K Part DStable
Peak10.9yr
Only marketed product, driving 100% of company revenue; tetracycline-class antibiotic with extended patent protection through 2037.
Help build intelligence for RAPHAS
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.